Navigation Links
Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
Date:11/14/2011

>(650) 575-1509Michelle Corral/BCC Partners

(415) 794-8662This press release contains forward-looking statements that reflect Nektar's current views as to the therapeutic potential of NKTR-192 to effectively treat acute pain while reducing abuse liability and certain serious side effects associated with traditional opioid therapies, preclinical observations regarding the biological effect of NKTR-192, the timing of the planned start of clinical studies for NKTR-192, the potential of Nektar's polymer conjugate technology platform, and the potential for certain of Nektar's other drug candidates and those of its collaboration partners. These forward-looking statements involve substantial risks and uncertainties including but not limited to one or more of the following: (i) the preclinical data for NKTR-192 described in this press release and presented at the 41st Annual Meeting of the Society for Neuroscience may not be predictive of future success in clinical trials; (ii) the commencement of a Phase 1 clinical study for NKTR-192 in the first half of 2012 could be delayed due to regulatory delays, the need to successfully complete certain toxicology studies, drug manufacturing challenges, and other important factors that can impact clinical development efforts; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates such as NKTR-192 is therefore very uncertain and unpredictable and one or more research and development programs could unexpectedly fail; (iv) Nektar's patent applications for its proprietary or partner drug candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (v) the outcome of any existing or future intellectual property or other litigation related to Nektar's proprietary drug candid
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
2. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
3. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
4. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
5. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
6. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
8. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
9. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
10. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
11. Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. ... inoperable solid tumor cancers, announced today that CEO Linda ... Phacilitate Immunotherapy Forum in Washington D.C. ... on January 26 at 10:30 a.m. EST at the Grand ...
(Date:1/23/2015)...  Pete Rose, baseball,s all-time hits leader, is the new spokesperson ... Ducere Pharma has announced. "Pete,s a Hall of ... him on board with Myoflex," said Ducere Pharma Chief Executive ... who is known across all generations. The passion and intensity ...
(Date:1/23/2015)... 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ) ... "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with the ... provides an update for shareholders detailing why a "YES" vote ... Dear Shareholders, As we reflect upon the ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... - Roche today announced,results of a small study ... (peginterferon alfa-2b),and ribavirin due to adverse events within ... weeks of treatment with PEGASYS(R),(peginterferon alfa-2a) and ribavirin. ... go on and complete a full course of,treatment ...
... ACCEPTED FOR REVIEW BY,FDA- , BASEL, Switzerland and ... SPPN) today welcomed the significant new results from,clinical ... the 22nd Annual Scientific Meeting,and Exposition of the ... These results confirm the favourable safety and,efficacy profile, ...
Cached Medicine Technology:Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 2Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 3Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 4Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 5Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 6New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 2New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 3New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 4New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 5New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 6New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 7New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 8New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 9New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 10New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 11
(Date:1/22/2015)... Illinois (PRWEB) January 22, 2015 Deer Path ... will host a Valentine’s Day Happy Hour from 3 p.m. to ... at 12500 Regency Parkway in Huntley, Illinois, serves adults with physical ... Hour event will include Valentine's Day treats, games and sweetheart-themed karaoke. ...
(Date:1/22/2015)... 2015 Woodloch Pines, an all-inclusive family ... by TripAdvisor as the number one best large hotel for ... the world for their annual Travelers’ Choice Awards. , ... The website is home to millions of unbiased and honest ...
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... The Nobel Prize, the correlation between genes and lifestyle, and ... of the topics that will be discussed at an international ... in Washington DC. The symposium has been arranged by Karolinska ... National Institutes of Health (NIH), and the Swedish embassy in ...
... of Pediatrics at the University of California, San Diego ... Diego has received a $10 million grant from the ... A world renowned physician-scientist in pediatric pulmonary medicine, ... UC San Diego and the Sanford-Burnham Medical Research Institute ...
... at UCLA,s Jonsson Comprehensive Cancer Center have discovered a ... development, a pathway that, when defective, helps promote the ... lymphoma and leukemia. , The new pathway, part of ... including some that have are known to cause cancer ...
... led by a Saint Louis University surgeon, investigators found ... receive C-sections at more than double normal rates despite ... possible. In addition, women reported lingering, yet often treatable, ... to post-traumatic stress disorder. The ...
... effort to boost research on women,s health over the last ... deaths among women due to cardiovascular disease, breast cancer, and ... Medicine. The effort has yielded less but still significant ... on women, added the committee that wrote the report. ...
... NOAA Coral Reef Watch monitoring system, coral bleaching is ... all year, NOAA,s models show a strong potential for ... that could be as severe as in 2005 when ... percent died at many sites across the Caribbean. Scientists ...
Cached Medicine News:Health News:Symposium in Washington with world-leading scientists 2Health News:UCLA cancer researchers discover new signaling pathway that controls cell development and cancer 2Health News:UCLA cancer researchers discover new signaling pathway that controls cell development and cancer 3Health News:Study finds high rate of c-sections after pelvic fractures 2Health News:Increased attention to women's health research has yielded gains on some important conditions, but progress lags on others 2Health News:Increased attention to women's health research has yielded gains on some important conditions, but progress lags on others 3Health News:Coral bleaching likely in Caribbean this year 2
... used screening test for determining the presence ... branded system is considered the manual standard, ... other system meets defined NCCLS/ICSH guidelines designed ... systems are also available for pediatric applications, ...
The HEMOCHRON Signature Elite offers state-of-the-art features like barcode scanning, internal Electronic Quality Control (EQC), QC Lockout and alphanumeric data entry for Patient Identification (PID...
Inquire...
The Minilyser offers a combination of three well proven instruments for fully automated processing of microplates. The Minilyser is the optimal fully automated ELISA and EIA equipment for laboratorie...
Medicine Products: